

Funder	Project Title	Funding	Strategic Plan Objective	Institution
National Institutes of Health	A Drug-Screening Platform for Autism Spectrum Disorders Using Human Neurons and Astrocytes	\$127,680	4.1	National Institute of Health - Intramural
Department of Defense - Army	Development of Novel Drugs Targeting Serotonin Receptors to Treat Motor, Social, Cognitive, and Sensory Domains of Autism Spectrum Disorder Using Mouse Models	\$0	4.1	Northeastern University
FRAXA Research Foundation (FRAXA)	Enhancing NMDA Receptor Signaling to Treat Fragile X Syndrome	\$45,000	4.1	Massachusetts Institute of Technology
FRAXA Research Foundation (FRAXA)	Pharmacological Tolerance in the Treatment of Fragile X Syndrome	\$90,000	4.1	Massachusetts Institute of Technology (MIT)
National Institutes of Health	Preclinical Imaging of Adolescent Cannabidiol on Brain Structure and Functional Connectivity	\$76,250	4.1	University of Florida
Department of Defense - Army	Development of Novel Drugs Targeting Serotonin Receptors to Treat Motor, Social, Cognitive, and Sensory Domains of Autism Spectrum Disorder Using Mouse Models	\$0	4.1	Mercer University
Simons Foundation	Translating Drug Discovery in Zebrafish and Mouse Models of ASD Risk Genes	\$123,833	4.1	Yale University
National Institutes of Health	Regulation of 22q11 Genes in Embryonic and Adult Forebrain	\$445,484	4.1	George Washington University
National Institutes of Health	4/5-The Autism Biomarkers Consortium for Clinical Trials	\$389,926	4.1	Yale University
National Institutes of Health	1/5-The Autism Biomarkers Consortium for Clinical Trials	\$417,095	4.1	Yale University
National Institutes of Health	Data Coordinating Core	\$928,131	4.1	Yale University
National Institutes of Health	3/5-The Autism Biomarkers Consortium for Clinical Trials	\$413,293	4.1	Yale University
National Institutes of Health	Administrative Core	\$923,289	4.1	Yale University
National Institutes of Health	5/5-The Autism Biomarkers Consortium for Clinical Trials	\$426,029	4.1	Yale University
National Institutes of Health	2/5-The Autism Biomarkers Consortium for Clinical Trials	\$427,653	4.1	Yale University
National Institutes of Health	Data Acquisition and Analysis Core	\$2,864,255	4.1	Yale University
FRAXA Research Foundation (FRAXA)	Reintroducing FMRP via Tat to Reduce Symptoms of Fragile X Syndrome	\$100,000	4.1	University of Calgary, Alberta
National Institutes of Health	Novel Therapy for Fragile X Syndrome	\$317,514	4.1	Epigen Biosciences, Inc.
Simons Foundation	Restoring FMRP to reverse Fragile X Syndrome	\$79,800	4.1	The University of Calgary
FRAXA Research Foundation (FRAXA)	Understanding and Reversing Hypersensitivity to Sounds in Fragile X Syndrome	\$90,000	4.1	University of California at Riverside School of Medicine
Simons Foundation	Detecting and Treating Social Impairments in a Monkey Model	\$164,588	4.1	Stanford University

Funder	Project Title	Funding	Strategic Plan Objective	Institution
Simons Foundation	Regulation of KCC2 as a target for treatment of Autism	\$75,000	4.1	University Laval
FRAXA Research Foundation (FRAXA)	Coffee, Tea, and Chocolate: Adenosine Receptors in Fragile X	\$90,000	4.1	Italian National Institute of Health
Brain & Behavior Research Foundation	Modulation of the Oxytocin System in a Mouse Model of Autism Spectrum Disorder (ASD)	\$16,079	4.1	University of the Basque Country
Simons Foundation	Neural circuitry linking oxytocin deficiency and social impairment in ASD	\$75,000	4.1	University of California, Los Angeles
National Institutes of Health	Novel Genetic Models of Autism	\$575,019	4.Core/Other	University of Alabama at Birmingham
National Institutes of Health	PTP1B Inhibitors for the Treatment of Rett Syndrome	\$204,406	4.1	Case Western Reserve University
National Institutes of Health	Chemicogenetic Rescue of Autism-Like Social Deficits in Shank3-Deficient Mice	\$79,750	4.1	State University of New York, Stony Brook
National Institutes of Health	Prefrontal Function in the Shank3-Deficient Rat: A First Rat Model for ASD	\$457,912	4.1	Icahn School of Medicine at Mount Sinai
Autism Speaks	PACT contract	\$350,250	4.1	Boston Children's Hospital
National Institutes of Health	Discovery of Novel Drugs for Autism	\$382,982	4.1	Asddr, Llc
National Institutes of Health	Developing a Prenatal Biologic Therapy to Mitigate ASD Risk from Maternal Autoantibodies to Caspr2	\$677,502	4.1	Spark2Flame, Inc.

